title: Treatment Failure After Image-Guided Percutaneous Radiofrequency Ablation (RFA) of Renal Tumors - A Systematic Review with Description of Type, Frequency, Risk Factors and Management.
abstract: BackgroundRadiofrequency ablation (RFA) is an established treatment for small renal tumors. The objective of this review is to systematically assess the type, frequency, risk factors and management of treatment failure after image-guided percutaneous RFA of renal tumors.Method10 studies (967 patients, 1033 tumors) with a mean/median follow-up of ≥ 30 months were systematically identified and analyzed.Results and ConclusionImage-guided percutaneous RFA of localized renal tumors is very effective. The most common type of treatment failure is residual unablated tumor (5.9 %), followed by local tumor progression (4.7 %). De novo tumors in the kidneys occur in 1.3 % of cases and extra-renal metastases in 2.0 %. Local tumor progression, de novo tumors in the kidneys and extra-renal metastases occur predominantly later than 12 months after initial RFA. Tumor size > 3 cm and central tumor location are the major risk factors for treatment failure. In the case of treatment failure, repeated RFA shows high success rates (86.3 % for residual unablated tumors and 87.5 % for local tumor progression).Key Points:· Treatment failure can be subdivided into residual unablated tumor and local tumor progression.. · Residual unablated tumor occurs in 5.9 % of cases.. · Local tumor progression occurs in 4.7 % of cases.. · Tumor size and location are the major risk factors for treatment failure.. · Repeated RFA is effective and commonly used for management..Citation Format· Vollherbst D, Bertheau R, Kauczor H et al. Treatment Failure After Image-Guided Percutaneous Radiofrequency Ablation (RFA) of Renal Tumors - A Systematic Review with Description of Type, Frequency, Risk Factors and Management. Fortschr Röntgenstr 2017; 189: 219 - 227.
authors.affiliation: Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: Dominik
authors.initials: D
authors.lastname: Vollherbst
authors.affiliation: Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: Robert
authors.initials: R
authors.lastname: Bertheau
authors.affiliation: Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: Hans-Ulrich
authors.initials: HU
authors.lastname: Kauczor
authors.affiliation: Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: Boris Alexis
authors.initials: BA
authors.lastname: Radeleff
authors.affiliation: Clinic for Radiology, Minimally-invasive Therapies and Nuclear Medicine, SLK-Kliniken, Heilbronn, Germany.
authors.forename: Philippe L
authors.initials: PL
authors.lastname: Pereira
authors.affiliation: Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: Christof-Matthias
authors.initials: CM
authors.lastname: Sommer
mesh_terms: D017115:Catheter Ablation / Q000401:mortality* / Q000706:statistics & numerical data; D006801:Humans; D015994:Incidence; D007680:Kidney Neoplasms / Q000401:mortality* / Q000601:surgery*; D011183:Postoperative Complications / Q000401:mortality* / Q000628:therapy*; D012307:Risk Factors; D025321:Surgery, Computer-Assisted / Q000401:mortality* / Q000706:statistics & numerical data; D015996:Survival Rate; D017211:Treatment Failure